About Shionogi
About Shionogi
About
About
Company Profile
SHIONOGI Journal
BRAND STATEMENT
Our Company
Compliance
Corporate Governance
SHIONOGI Infectious Disease Weeks
Message from Top Management
Philosophy
Business Strategy
Business Activities
Shionogi's Strength
Group Companies
History
Policies
Compliance
Compliance Promotion Structure and Initiatives
Commitment to Tax Compliance
Ensuring High Ethical Standards and Transparency in Business Activities
Corporate Governance
Basic Views and Guidelines on Corporate Governance
Corporate Governance System
Board
Shareholdings
Sustainability
Sustainability
Sustainability
Sustainability
Material Issues
Environment
Society
Governance
Address the problem of antimicrobial resistance (AMR)
Access to healthcare
Stakeholder Engagement
Sustainability disclosure and evaluation
Sustainability-related information
Environment
Policy / Approach
Environmental Topics
Initiatives for Each Theme
Information Disclosure / Data
Society
Ensuring quality and safety in products and services
Attractive workplace
Respect Human Rights
Supply Chain Management
Social contribution activities
Governance
Corporate Governance
Risk Management
Compliance
Address the problem of antimicrobial resistance (AMR)
Our promise
Background of addressing the problem of antimicrobial resistance (AMR)
Long-term commitment to improving R&D to provide novel treatments for infectious diseases
Combating challenge of AMR
AMR
Shionogi AMR Position Paper
Access to healthcare
Developing innovative therapies to address unmet needs
Promote proper use of medicines
Improving affordability for patients in need
Improving access to healthcare services in developing countries
Stakeholder Engagement
Engagement with shareholders and investors
Engagement with customers
Engagement with employees
Engagement with society
Annual Report / Integrated Report / Environment Report
Data
External evaluation
About United Nations Global Compact
Innovation
Innovation
Innovation
Innovation
R&D
Partnering
Pipeline
IP Strategy
Wastewater-based Epidemiology Surveillance Service
R&D
Overview of R&D
Drug discovery
Clinical Development
Digital therapy
Investigator-Initiated Research
Open Innovation
News
SPmenu
SPmenu
About
Back
About
Company Profile
SHIONOGI Journal
BRAND STATEMENT
Our Company
Compliance
Corporate Governance
SHIONOGI Infectious Disease Weeks
Back
Message from Top Management
Philosophy
Business Strategy
Business Activities
Shionogi's Strength
Group Companies
History
Policies
Back
Compliance
SHIONOGI Group Compliance Policy
Compliance Promotion Structure and Initiatives
Commitment to Tax Compliance
Ensuring High Ethical Standards and Transparency in Business Activities
Back
Corporate Governance
Basic Views and Guidelines on Corporate Governance
Corporate Governance System
Board
Shareholdings
Sustainability
Back
Sustainability
Material Issues
Environment
Society
Governance
Address the problem of antimicrobial resistance (AMR)
Access to healthcare
Stakeholder Engagement
Sustainability disclosure and evaluation
Sustainability-related information
Back
Environment
Policy / Approach
Environmental Topics
Initiatives for Each Theme
Information Disclosure / Data
Back
Society
Ensuring quality and safety in products and services
Attractive workplace
Respect Human Rights
Supply Chain Management
Social contribution activities
Back
Governance
Corporate Governance
Risk Management
Compliance
Back
Address the problem of antimicrobial resistance (AMR)
Our promise
Background of addressing the problem of antimicrobial resistance (AMR)
Long-term commitment to improving R&D to provide novel treatments for infectious diseases
Combating challenge of AMR
AMR
Shionogi AMR Position Paper
Back
Access to healthcare
Developing innovative therapies to address unmet needs
Promote proper use of medicines
Improving affordability for patients in need
Improving access to healthcare services in developing countries
Back
Stakeholder Engagement
Engagement with shareholders and investors
Engagement with customers
Engagement with employees
Engagement with society
Back
Annual Report / Integrated Report / Environment Report
Data
External evaluation
Back
About United Nations Global Compact
Innovation
Back
Innovation
R&D
Partnering
Pipeline
IP Strategy
Wastewater-based Epidemiology Surveillance Service
Back
R&D
Overview of R&D
Drug discovery
Clinical Development
Digital therapy
Investigator-Initiated Research
Open Innovation
News
Investors
Contact Us
Careers
Search
English
Worldwide
HOME
Investors
IR Library
Financial Results / Supplement
Financial Results / Supplement
Financial Data
FY2024
3Q Financial Results
3Q Supplement
2Q Financial Results
2Q Supplement
1Q Financial Results
1Q Supplement
Click here for past reports
FY2023
FY2023 Financial Results
FY2023 Supplement
3Q Financial Results
3Q Supplement
2Q Financial Results
2Q Supplement
2Q Press conference
1Q Financial Results Supplement
FY2022
FY2022 Financial Results
FY2022 Supplement
FY2022 Press conference
3Q Financial Results Supplement
2Q Financial Results
2Q Supplement
2Q press conference
1Q Financial Results Supplement
FY2021
FY2021 Financial Results
FY2021 Supplement
FY2021 Press conference
3Q Financial Results Supplement
2Q Financial Results
2Q Supplement
2Q Press conference
1Q Financial Results Supplement
FY2020
FY2020 Financial Results
FY2020 Supplement
FY2020 Press conference
3Q Financial Results Supplement
2Q Financial Results
2Q Supplement
2Q Press conference
1Q Financial Results Supplement
FY2019
FY2019 Financial Results (IFRS)
FY2019 Financial Results
FY2019 Supplement
FY2019 Press conference
3Q Financial Results Supplement
2Q Financial Results
2Q Supplement
2Q Press conference
1Q Financial Results Supplement
FY2018
FY2018 Financial Results
FY2018 Supplement
FY2018 Press conference
3Q Financial Results Supplement
2Q Financial Results
2Q Supplement
2Q Press conference
1Q Financial Results Supplement
FY2017
FY2017 Financial Results
FY2017 Supplement
FY2017 Press conference
3Q Financial Results_Supplement
2Q Financial Results
2Q Supplement
2Q Press conference
1Q Financial Results Supplement
FY2016
FY2016 Financial Results
FY2016 Supplement
FY2016 Press conference
3Q Financial Results Supplement
2Q Financial Results
2Q Supplement
2Q Press conference
1Q Financial Results_Supplement
FY2015
FY2015 Financial Results
FY2015 Supplement
FY2015 Press conference
3Q Financial Results_Supplement
2Q Financial Results
2Q Supplement
2Q Press conference
1Q Financial Results_Supplement
FY2014
FY2014 Financial Results
FY2014 Supplement
FY2014 Press conference
3Q Financial Results_Supplement
2Q Financial Results
2Q Supplement
2Q Press conference
1Q Financial Results_Supplement
FY2013
FY2013 Financial Results
FY2013 Supplement
FY2013 Press conference
3Q Financial Results
2Q Financial Results
2Q Supplement
2Q Press conference
1Q Financial Results_Supplement
FY2012
Financial Results
Supplement
Press conference
3Q Financial Results
2Q Financial Results
Supplement
Press conference
1Q Financial Results
FY2011
Financial Results
Supplement
Press conference
3Q Financial Results
2Q Financial Results
Supplement
Press conference
1Q Financial Results
FY2010
Financial Results
Supplement
Press conference
3Q Financial Results
2Q Financial Results
Supplement
Press conference
1Q Financial Results
FY2009
Financial Results
Supplement
Press conference
3Q Financial Results
2Q Financial Results
Supplement
Press conference
1Q Financial Results
FY2008
Financial Statements
Supplement
3Q Financial Results
2Q Financial Results
Supplement
1Q Financial Results
FY2007
Financial Statements
Supplement
3Q Financial Results (Consolidated)
Interim Financial Statements
Supplement
1Q Financial Results (Consolidated)
FY2006
Financial Statements
Supplement
3Q Financial Results (Consolidated)
Interim Financial Statements(Consolidated)
Interim Financial Statements(Non-Consolidated)
Supplement
1Q Financial Results (Consolidated)
FY2005
Financial Statements(Consolidated)
Financial Statements(Non-Consolidated)
Supplement
3Q Financial Results (Consolidated)
Interim Financial Statements(Consolidated)
Interim Financial Statements(Non-Consolidated)
Supplement
1Q Financial Results (Consolidated)
FY2004
Financial Statements(Consolidated)
Financial Statements(Non-Consolidated)
Supplement
3Q Financial Results (Consolidated)
Interim Financial Statements(Consolidated)
Interim Financial Statements(Non-Consolidated)
Supplement
1Q Financial Results (Consolidated)
